Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study

This publication has 40 references indexed in Scilit:

• MSR190 Psychometric Analysis of the Patient-Reported Plexiform Neurofibromas Quality of Life Measure Using KOMET Study Data
  Value in Health, 2024
• The development of the PlexiQoL: A patient‐reported outcome measure for adults with neurofibromatosis type 1‐associated plexiform neurofibromas
  Molecular Genetics & Genomic Medicine, 2020
• Substantial pain burden in frequency, intensity, interference and chronicity among children and adults with neurofibromatosis Type 1
  American Journal of Medical Genetics Part A, 2019
• Lifespan Development: Symptoms Experienced by Individuals with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas from Childhood into Adulthood
  Journal of Clinical Psychology in Medical Settings, 2018
• Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social‐emotional functioning, and quality of life
  American Journal of Medical Genetics Part A, 2015
• Pediatric Plexiform Neurofibromas: Impact on Morbidity and Mortality in Neurofibromatosis Type 1
  The Journal of Pediatrics, 2012
• Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Frequency and Associated Clinical Deficits
  The Journal of Pediatrics, 2011
• Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale
  European journal of pain, 2004
• Prognostic signs in the surgical management of plexiform neurofibroma: The Children’s Hospital of Philadelphia experience, 1974-1994
  The Journal of Pediatrics, 1997
• Comparative analysis of two rates
  Statistics in Medicine, 1985